O diferencial estratégico10,11
que seu negócio precisa 
No setor da saúde, quando se trata de administração de medicamentos, sistemas injetáveis precisam estar de acordo com as necessidades de stakeholders distintos, como empresas e hospitais. Essa tecnologia pode atender necessidades críticas dessa cadeia farmacêutica, elas podem servir como uma estratégia de diferenciação especialmente em mercados dominados por frascos e ampolas10,11*.
Discovery. Diagnostics. Delivery.
Can be accessed on our Customer Learning Portal. The e-learning courses offer detailed and solution focused training to help better understand how to solve for common scenarios.
Discovery. Diagnostics. Delivery.
Can be accessed on our Customer Learning Portal. The e-learning courses offer detailed and solution focused training to help better understand how to solve for common scenarios.
Experts from around the globe describe the intersection between patient and healthcare worker safety, focusing on techniques to improve both occupational and public health.
Webinar Objectives:
- Describe the current global impact of bloodborne disease
- Describe occupational exposure incidents for needlesticks and sharps injuries
- Define safety as a function of focus for both patient and health worker, to reduce overall bloodborne disease
- Provide guidance on the importance of prevention programs including use of safer medical devices, immunization/vaccination programs, and safe clinical practices
- Illustrate an effective pathway for reporting exposure incidents and injuries
- Define processes for post-exposure medical treatment and prophylaxis
- Share global experiences from key stakeholders responsible for sharps safety and public health programs around the world
Save Your Seat
Você está pronto para a inovação?
Nos últimos anos, dados sugerem que alguma empresas farmacêuticas que lançaram medicamentos em seringas preenchidas, se beneficiaram com um crescimento favorável em seu negócio, no mercado internacional.10
Estudos de caso:
De acordo com dados da IQVIA, empresas Europeias e Indianas, conseguiram obter um aumento em 71% em suas vendas, ao lançar Ácido Ibandronico em seringas preenchidas10**
De acordo com dados da IQVIA, empresas Europeias, ao lançar Fenilefrina em uma seringa preenchida, conseguiram incrementar 44% em vendas em um mercado dominado por ampolas10***
Pellentesque habitant morbi tristique senectus et netus et malesuada fames ac turpis egestas vestibulum tortor quam.
Pellentesque habitant morbi tristique senectus et netus et malesuada fames ac turpis egestas vestibulum tortor quam.
Pellentesque habitant morbi tristique senectus et netus et malesuada fames ac turpis egestas vestibulum tortor quam.
Pellentesque habitant morbi tristique senectus et netus et malesuada fames ac turpis egestas vestibulum tortor quam.
Pellentesque habitant morbi tristique senectus et netus et malesuada fames ac turpis egestas vestibulum tortor quam.
Pellentesque habitant morbi tristique senectus et netus et malesuada fames ac turpis egestas vestibulum tortor quam.
Video title here
Quer conhecer mais sobre o universo das seringas preenchidas e oportunidades para seu negócio?
Fale com nossa equipe! Preparamos um conteúdo exclusivo para quem se cadastrar em nossa plataforma.
Conheça as seringas preenchidas e saiba como elas podem oferecer diferenciação de mercado, ganho de market share e oportunidades ao seu negócio. Basta preencher seus dados para receber um infográfico exclusivo e o contato de nossos especialistas.
Hospitals and healthcare facilities
BD is a market leader in hospital products that can reduce the incidence of sharps injuries and exposure to bloodborne pathogens. Patient safety has been a focus of BD innovation for years, not only in the United States but also around the world. Working closely with organizations like the International Safety Center (EPINet) is an important part of our efforts to keep patients and workers safe.
Safety syringes and needles >>
Hazardous drug safety >>
Infection prevention >>
Segundo IQVIA Retail Market de 2018, uma empresa na Europa conquistou um crescimento de 15% nos números de vendas em apenas 4 anos após a adoção dos sistemas de seringas preenchidas, performando com mais eficiência, atingindo a liderança em vendas.10,11
A partir dos dados da IQVIA Retail Market, uma empresa indiana se encontrava em uma situação parecida. Após a adoção das seringas preenchidas teve crescimento de quase 7% na vendas de seus medicamentos e capaz de se tornar uma das top 4 empresas farmacêuticas no mercado europeu.10,11
Pellentesque habitant morbi tristique senectus et netus et malesuada fames ac turpis egestas vestibulum tortor quam.
Pellentesque habitant morbi tristique senectus et netus et malesuada fames ac turpis egestas vestibulum tortor quam.
Store Tab
360° rotation knob is effectively sized, contoured and located to enable easy instrument rotation.
360° rotation knob is effectively sized
360° rotation knob is effectively sized
360° rotation knob is effectively sized
Hospitals and healthcare facilities
BD is a market leader in hospital products that can reduce the incidence of sharps injuries and exposure to bloodborne pathogens. Patient safety has been a focus of BD innovation for years, not only in the United States but also around the world. Working closely with organizations like the International Safety Center (EPINet) is an important part of our efforts to keep patients and workers safe.
Safety syringes and needles >>
Hazardous drug safety >>
Infection prevention >>
Hospitals and healthcare facilities
BD is a market leader in hospital products that can reduce the incidence of sharps injuries and exposure to bloodborne pathogens. Patient safety has been a focus of BD innovation for years, not only in the United States but also around the world. Working closely with organizations like the International Safety Center (EPINet) is an important part of our efforts to keep patients and workers safe.
Safety syringes and needles >>
Hazardous drug safety >>
Infection prevention >>
Pellentesque habitant morbi tristique senectus et netus et malesuada fames ac turpis egestas vestibulum tortor quam.
Pellentesque habitant morbi tristique senectus et netus et malesuada fames ac turpis egestas vestibulum tortor quam.
Let's have a conversation
REFERÊNCIAS:
1. Vogl TJ, Wessling J, Buerke B. Acta Radiol. 2012;53(8):914-920 Continued multiple use from vials/bottles was almost 100-fold greater compared with PFSs (80.22% vs. 0.83%), respectively. An observational study of 10,836 patients to evaluate the efficiency and safety of ioversol PFS.
2. Adapa RM, Mani V, Murray LJ, et al. Br J Anaesth. 2012;109(5):729-734. Medication dosing errors were 17.0 times less likely when PFSs were used (95% CI 5.2–55.5) (p < 0.001) based on a randomized, blinded, simulated septic shock patient study with 48 nurses comparing ampule use to PFSs.
3. Rottenkolber D, et al. Value in Health. 2012; 868–875Subhi Y, et al. Dan Med J. 2016. Annual total treatment costs in ADE patients (€9.67 million) exceeded those in non-ADE patients (€7.83 million) by €1.84 million and required an extended hospital stay of 2.9 (median 1.0 day) extra days (P < 0.0001). Retrospective medical record-based study performed from the hospitals’ perspective based on administrative accounting data from three hospitals (49,462 patients) in Germany.
4. Subhi Y, et al. Dan Med J. 2016;63(4):A5214.. Observational time/motion study comparing PFS preparation to syringe and vials (n = 56 ea) in a multicenter study. PFSs eliminated 6 of 10 steps in the preparation process. Total preparation time was 40.3 ± 6.7s using vials, and 16.9 ± 3.6s for PFS use, saving 25.5 sec (p < 0.0001).
5. USP 35 General Information / <1151> Pharmaceutical Dosage Forms p765-766. © 2012. For a 0.5 ml vial/ampoule, the USP recommends 20-25% overfill. In contrast, for a 0.5 ml PFS, overfill is less than 2%.
6. Makwana S, Basu B, Makasana Y, DharamsiInt A. Prefilled syringes: An innovation in parenteral packaging. J Pharm Investig. 2011 Oct-Dec; 1(4): 200–206.
7. Parikh Anish. Pre-Filled Syringes: Development Challenges and the Value of Partnership
8. Prefilled Syringes Market (Glass and Plastic)–Global Industry Analysis, Size,Volume, Share, Growth, Trends and Forecast, 2013-2019, Research and Markets, http://www.researchandmarkets.com/research/mrs99n/prefilled.
9. The Prefilled Syringe Market report, Roots Analysis, July 2013, http://www.rootsanalysis.com/reports/view_document.html?report_id=18.
10. Based on extracted IQVIA – Smart MIDAS Datapack 2017-2019
*based on IQVIA Ex Manufacturing price list
11. Considerations and Options for Prefilled Syringes [External study - White paper], Illinois, USA; Baxter Healthcare Corporation, 2019
12. Tian, L., et al., Value in Health, 2016. 19(7): p. A861. A meta-analysis identified 46 English and Chinese observational and randomized clinical trials published between 1974 and 2015 analyzing prefilled flush syringes for intravascular device maintenance. These studies found that prefilled flush syringes reduce the risk of needle-stick injuries among healthcare workers (OR 0.17, 95% CI:0.06, 0.45, p= 0.0004).
13. Lahue, BJ, et. al. American Health & Drug Benefits. November/December 2012, 5(7); p. 413-422
* Statement relevant to drugs delivered in fixed dose formats
** Market situation - Innovator drug in prefilled syringe is facing loss of its market exclusivity, leading to entry of competitors
Competitors launching generic versions in prefilled syringe, vial and ampoule formats.
Indication - Ibandronic acid, Osteoporosis non biologics, ATC2: M5 Other musculo-skeletal
Pharma players - EU-based generic players, India-based generic players launching in EU
Business impact: Stronger market performance of the generic versions in prefilled syringes which grew to ~71% revenue share versus vials which declined to ~8%.
*** Market situation - Generic drug in EU exclusively present in ampoules
New players entering the market with prefilled
syringe presentations Competitors launching generic versions in prefilled syringe, vial and ampoule formats.
Indication – Phenylephrine, Treatment of hypotensive states, e.g. circulatory failure, during spinal anaesthesia or drug-induced hypotension, ATC2: C1 Cardiac therapy
Pharma players - 5 EU-based companies playing in the sterile injectable space, as generic players or compounders, launch generic versions in a prefilled syringe in EU
Business impact: Companies launching in PFS haved gained up to 44% revenue share in 5 years after market launch
BD-50906
BD is committed to keeping your personal data protected and secure. More information on how we protect your personal data can be found in our privacy statement and our cookie policy.